"A Phase 3, Global, Randomized, Double-Blind Trial of Tazemetostat in Combination with Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma"

Administered By

Awarded By

Contributors

Start/End

  • August 6, 2020 - July 31, 2025